01 Advancement in Oral Delivery TechnologiesThe advancement in oral delivery technologies, particularly nanoparticles and microemulsions, is transforming drug administration by enhancing bioavailability, stability, and targeted delivery. These innovations address challenges such as enzymatic degradation and poor permeability, making oral formulations more effective for biologics and peptides.A 2024 study in Science Advances introduced a groundbreaking ionic liquid-based nano-carrier that safeguards insulin from stomach degradation while enhancing its absorption in the intestines. This breakthrough represents a major step toward improving oral insulin delivery, potentially reducing the need for injections for diabetic patients. Utilizing ultra-small nano-scale materials, the carrier shields insulin from gastric acids and ensures efficient transport to target areas in the body.Additionally, self-emulsifying drug delivery systems (SEDDS) and lipid-based nanoparticles are gaining traction, offering controlled release mechanisms that improve therapeutic efficacy and patient compliance.
01 Rising Prevalence of Chronic DiseasesThe rising prevalence of chronic diseases is a major driver of growth in the healthcare market, fueling demand for innovative treatments and advanced drug delivery systems. As lifestyles evolve, factors such as sedentary behavior, poor diet, and aging populations are increasing the burden of chronic illnesses worldwide.This surge in chronic conditions underscores the need for enhanced preventive healthcare, precision medicine, and biologics. Companies are investing in targeted therapies, AI-driven diagnostics, and patient-friendly formulations to address this growing demand.
01 Low BioavailabilityA significant restraint in the global oral proteins and peptides market is the inherently low bioavailability of these therapeutics when administered orally. The gastrointestinal tract presents multiple barriers that drastically reduce absorption, including enzymatic degradation by digestive proteases, poor permeability across the intestinal epithelium due to the large molecular size and hydrophilic nature of biologics, and instability in the harsh acidic environment of the stomach.These physiological challenges typically result in bioavailability levels below 1-2%, necessitating substantially higher doses to achieve therapeutic effects compared to parenteral administration. This limitation not only affects drug efficacy but also increases development costs and complicates formulation strategies, presenting a persistent obstacle to the widespread adoption of oral protein and peptide therapies in clinical practice.
01 Increased Utilization in New Therapeutic Areas like Nash and Alzheimer's DiseaseThe expanding role of oral peptides in new therapeutic areas like NASH and Alzheimer's disease presents a promising market opportunity. In NASH, peptides are being explored for their ability to regulate metabolic pathways and reduce liver inflammation. Drugs like semaglutide, initially developed for diabetes, are showing efficacy in improving liver histology and reducing disease progression. Additionally, in Alzheimer's treatment, researchers are exploring peptide-based approaches to combat neurodegeneration.These advancements suggest that peptide-based therapies could transform treatment landscapes, offering non-invasive solutions for complex diseases with improved patient compliance and broader accessibility.
March 2026 Entera Bio advanced its oral peptide pipeline through expanded clinical development programs targeting endocrine and metabolic disorders.
October 2025 Biocon expanded research collaborations focused on oral peptide drug delivery technologies to accelerate the development of next-generation biologic therapies.
July 2025 Eli Lilly announced positive Phase III clinical results for orforglipron, strengthening its pipeline of oral therapies for metabolic diseases.
May 2025 Novo Nordisk received U.S. FDA approval for oral semaglutide at a higher-dose formulation for adults with type 2 diabetes, expanding its oral peptide therapy portfolio.